AI Article Synopsis
- Lung transplantation has greatly improved in the last 50 years, becoming the preferred treatment for severe respiratory diseases, especially in the early recovery phase.
- A major challenge in lung transplant survival is chronic lung allograft dysfunction (CLAD), which affects about 50% of recipients within five years.
- Ongoing research into ex vivo lung perfusion (EVLP) and bioengineered lungs aims to increase the availability of suitable donor lungs and reduce the chances of rejection, offering hope for better long-term outcomes.
Article Abstract
Over the past five decades, outcomes for lung transplantation have significantly improved in the early post-operative period, such that lung transplant is now the gold standard treatment for end-stage respiratory disease. The major limitation that impacts lung transplant survival rates is the development of chronic lung allograft dysfunction (CLAD). CLAD affects around 50% of lung transplant recipients within five years of transplantation. We must also consider other factors impacting the survival rate such as the surgical technique (single versus double lung transplant), along with donor and recipient characteristics. The future is promising, with more research looking into ex vivo lung perfusion (EVLP) and bioengineered lungs, with the hope of increasing the donor pool and decreasing the risk of graft rejection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531612 | PMC |
| http://dx.doi.org/10.3390/jcdd10090397 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!